- Home
- CGNT vs CRGX Comparison
CGNT vs CRGX Comparison
Compare CGNT & CRGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGNT
- CRGX
- Stock Information
- Founded
- CGNT 2020
- CRGX 2021
- Country
- CGNT Israel
- CRGX United States
- Employees
- CGNT N/A
- CRGX N/A
- Industry
- CGNT Computer Software: Prepackaged Software
- CRGX
- Sector
- CGNT Technology
- CRGX
- Exchange
- CGNT Nasdaq
- CRGX Nasdaq
- Market Cap
- CGNT 649.9M
- CRGX 628.6M
- IPO Year
- CGNT N/A
- CRGX 2023
- Fundamental
- Price
- CGNT $10.43
- CRGX $3.76
- Analyst Decision
- CGNT Hold
- CRGX Hold
- Analyst Count
- CGNT 3
- CRGX 7
- Target Price
- CGNT $8.25
- CRGX $4.67
- AVG Volume (30 Days)
- CGNT 274.7K
- CRGX 1.9M
- Earning Date
- CGNT 12-11-2024
- CRGX 03-20-2025
- Dividend Yield
- CGNT N/A
- CRGX N/A
- EPS Growth
- CGNT N/A
- CRGX N/A
- EPS
- CGNT N/A
- CRGX N/A
- Revenue
- CGNT $339,818,000.00
- CRGX N/A
- Revenue This Year
- CGNT $13.67
- CRGX N/A
- Revenue Next Year
- CGNT $6.92
- CRGX N/A
- P/E Ratio
- CGNT N/A
- CRGX N/A
- Revenue Growth
- CGNT 12.16
- CRGX N/A
- 52 Week Low
- CGNT $6.21
- CRGX $3.00
- 52 Week High
- CGNT $9.97
- CRGX $33.92
- Technical
- Relative Strength Index (RSI)
- CGNT 71.88
- CRGX 20.88
- Support Level
- CGNT $8.83
- CRGX $3.00
- Resistance Level
- CGNT $9.55
- CRGX $3.88
- Average True Range (ATR)
- CGNT 0.40
- CRGX 0.92
- MACD
- CGNT 0.06
- CRGX -1.00
- Stochastic Oscillator
- CGNT 100.00
- CRGX 5.99
About CGNT Cognyte Software Ltd.
Cognyte Software Ltd provides security analytics software that empowers governments and enterprises with Actionable Intelligence. Its interface software is designed to help customers accelerate and improve the effectiveness of investigations and decision-making.
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platform technologies, and manufacturing plan are designed to directly address the key limitations of approved cell therapies, including limited durability of effect, suboptimal safety and unreliable supply. The company's program, CRG-022, is a novel CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in a vast majority of B-cell malignancies.